Non-Hodgkin-Lymphome

Zusammenfassung

Die malignen Non-Hodgkin-Lymphome (NHL) stellen eine heterogene Krankheitsgruppe dar. Es existieren weder eine einheitliche, weltweit akzeptierte histologische Einteilung, noch allgemein anerkannte Richtlinien für die Stadieneinteilung und Diagnostik. Jedoch wurden in den vergangenen Jahren große Fortschritte im Verständnis der pathophysiologischen Grundlagen erreicht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Binet JL, Catovsky D, Chandra P et al. (1981) Chronic lymphocytic leukaemia; Proposal for a revised prognostic staging system. Br J Haematol 48:365–367CrossRefGoogle Scholar
  2. 2.
    Cabanillas F, Valasquez WS, McLaughlin P et al. (1988) Results of Recent Salvage Chemotherapy Regimens for Lymphoma and Hodgkin’s Disease. Sem Hematol 25 [Suppl 2]: 147–50Google Scholar
  3. 3.
    Cheson BD, Martin A (1987) Clinical trials in hairy cell leukemia: current status and future directions. Ann Intern Med 106:871–878PubMedCrossRefGoogle Scholar
  4. 4.
    De Angelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635–643Google Scholar
  5. 5.
    Fischbach W, Kestel W, Kirchner T (1989) Malignant Lymphomas of the Upper Gastrointestinal Tract. Results of a prospective study in 103 patients. Blut 59: 346 (Abstr)Google Scholar
  6. 6.
    Fisher IR, De Vita VT, Hubbard SM et al. (1983) Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98:304–309PubMedCrossRefGoogle Scholar
  7. 7.
    Fisher RI, Gaynor ER, Dahlberg S, Oken M, Grogan TM, Evonne M, Mize M, Glick JH, Coltman CA (1993) Comparison of a standard regimen (chop) with three intensive chemotherapy regimes for advanced non-Hodgkin-Lymphoma. N Engl J Med 328:1002–1006PubMedCrossRefGoogle Scholar
  8. 8.
    Foon KA, Rai KR, Gale RM (1990) Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 113:525–539PubMedCrossRefGoogle Scholar
  9. 9.
    French cooperative group on chronic lymphocytic leukemia (1989) Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 73: 334–340CrossRefGoogle Scholar
  10. 10.
    French cooperative group on chronic lymphocytic leukaemia (1990) A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75:1422–1425Google Scholar
  11. 11.
    French cooperative group on chronic lymphocytic leukaemia (1990) Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic laukemia (stage A): Results of a randomized clinical trial on 612 patients. Blood 75:1414–1421Google Scholar
  12. 12.
    Gribben JG, Goldstone AH, Lich DC et al. (1989) Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with Non-Hodgkin’s Lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 7:1621–1629PubMedGoogle Scholar
  13. 13.
    Hartenstein R, Abenardt W (1990) Behandlung maligner Körperhöhlenergüsse. In: Huhn D, Herrmann R (Hrsg) Medikamentöse Therapie maligner Erkrankungen. Fischer, StuttgartGoogle Scholar
  14. 14.
    Hintze RE (1989) Endoskopische Diagnostik der gastro-intestinalen Lymphome. Verdauungskrankeiten 7: 18–24Google Scholar
  15. 15.
    Hu E, Levine J (1986) Chemotherapy of malignant thymoma. Case report and review of the Literature. Cancer 57: 1101–1104PubMedCrossRefGoogle Scholar
  16. 16.
    Huhn D (1980) Therapie bei Lymphadenose (CLL). Münch Med Wochenschr 122:501–503Google Scholar
  17. 17.
    Huhn D (1983) Nicht-Hodgkin-Lymphome — einige aktuelle Aspekte der klinischen Diagnostik und Therapie. Klin Wochenschr 61:435–443PubMedCrossRefGoogle Scholar
  18. 18.
    Huhn D (1989) Gastrointestinale Lymphome beim erworbenen Immunmangelsyndrom. Verdauungskrankheiten 7: 48–52Google Scholar
  19. 19.
    Internatinal Workshop on chronic lymphocytic leukemia (1989) Chronic lymphocytic leukemia. Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 110:236–238CrossRefGoogle Scholar
  20. 20.
    Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327:1056–61PubMedCrossRefGoogle Scholar
  21. 21.
    Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10:371–377PubMedGoogle Scholar
  22. 22.
    Kaye FJ, Bunn PA Jr, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of Mycosis Fungoides. N Engl J Med 321:1784–1790PubMedCrossRefGoogle Scholar
  23. 23.
    Keating MJ, Kantarjian H, O’Brian S, Koller C, Talpaz M, Schaner J, Childs CC, Freireich EJ, McCredie KB (1991) fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9: 44–49PubMedGoogle Scholar
  24. 24.
    Knospe WH, Loeb V, Huguley CM (1974) Bi-weekly chlorambucil for chronic lymphocytic leukemia. Cancer 33: 555–562PubMedCrossRefGoogle Scholar
  25. 25.
    Krauseneck P (1990) Gehirntumoren. In: Huhn D, Herrmann R (Hrsg) Medikamentöse Therapie maligner Erkrankungen, Fischer, Stuttgart New YorkGoogle Scholar
  26. 26.
    Kuzel TM, Roenigk HH, Rosen ST (1991) Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis and therapy. J Clin Oncol 9:1298–1313PubMedGoogle Scholar
  27. 27.
    Longo DL, Glatstein E, Duffey PL et al. (1989) Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 7:1295–1302PubMedGoogle Scholar
  28. 28.
    McLaughlin P, Fuller LM, Velasquez WS et al. (1987) Stage III Follicular Lymphoma: Durable Remissions With a Combined Chemotherapy-Radiotherapy Regimen. J Clin Oncol 5:867–874PubMedGoogle Scholar
  29. 29.
    Meusers P, Engelhard M, Bartels H et al. (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365 –380PubMedCrossRefGoogle Scholar
  30. 30.
    Oertel J, Oertel B, Kastner M et al. (1988) The value of immunocytochemical staining of lymph node aspirates in diagnostic cytology. Br J Haemat 70:307–316CrossRefGoogle Scholar
  31. 31.
    Raphael B, Anderson JW, Silber R, Oken M, Moore D, Bennett J, Bonner H, Hahn R, Knospe WH, Mazza J, Glick J (1991) Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone as initial treatment for chronic lymphocytic leukemia: Longterm follow-up of an eastern cooperative oncology group randomized clinical trial. J Clin Oncol 9:770–776PubMedGoogle Scholar
  32. 32.
    Serke M, Huhn D, Dienemann D et al. (1988) HIV-Related Malignant Lymphomas. Klin Wochenschr 66:682–685PubMedCrossRefGoogle Scholar
  33. 33.
    Schipp MA, Yeap YB, Harrington DP (1990) The m-BA-COD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8:84–93Google Scholar
  34. 34.
    Siegert W, Hackl G, Löhrs U, Huhn D (1985) Non-Hodgkin’s Lymphomas Presenting with Gastrointestinal Involvement. Klin Wochenschr 63:56–61PubMedCrossRefGoogle Scholar
  35. 35.
    Siegert W, Huhn D, Neubauer A et al. (1988) Multizentrische prospektive risikoadaptierte Studie zur Therapie von Non-Hodgkin-Lymphomen hoher Malignität. Einsatz von COP-BLAM/IMVP-16 und randomisierte adjuvante Strahlentherapie. Onkologie 11:30–34PubMedCrossRefGoogle Scholar
  36. 36.
    Siegert W, Agthe W, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, Kuse R, Tiemann M, Lennert K, Huhn D (1992) T-cell lymphoma of AILD-Type — results of a multicentric prospective evaluation of a standardized treatment. Ann Intern Med 117:364–370PubMedCrossRefGoogle Scholar
  37. 37.
    Stein H, Sperling M, Dienemann D et al. (1988) Identification of a T cell lymphoma category derived from intestinal-mucosa-associated T cells. Lancet II: 1053–1054CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • D. Huhn

There are no affiliations available

Personalised recommendations